CTOs on the Move

Graybug Vision

www.graybug.vision

 
Every day, Graybug Vision works relentlessly to make healthy vision more accessible and more manageable for patients with chronic vision-threatening eye diseases. We are a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of chronic diseases of the retina and optic nerve. Our novel technologies are designed to release drugs in ocular tissue at a controlled rate for up to 12 months in order to improve patient compliance, reduce healthcare burdens and, ultimately, deliver better clinical outcomes.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.graybug.vision
  • 275 Shoreline Drive Suite 450
    Redwood City, CA USA 94065
  • Phone: 650.487.2800

Executives

Name Title Contact Details

Similar Companies

Axcan Pharma Inc

Axcan Pharma Inc is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lyne Laboratories

Lyne Laboratories is a Brockton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diffusion Pharmaceuticals

Neuralink is a team of exceptionally talented people. We are creating the future of brain-machine interfaces: building devices now that will help people with paralysis and inventing new technologies that will expand our abilities, our community, and our world. Our goal is to build a system with at least two orders of magnitude more communication channels (electrodes) than current clinically-approved devices. This system needs to be safe, it must have fully wireless communication through the skin, and it has to be ready for patients to take home and use on their own. Our device, called the Link, will be able to record from 1024 electrodes and is designed to meet these criteria.

Theseus Pharmaceuticals

Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).

ALDA Pharmaceuticals

ALDA Pharmaceuticals Corp. is a Richmond, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.